Oral administration of Bifidobacterium longum ameliorates influenza virus infection in mice. 2011

Noriyuki Iwabuchi, and Jin-Zhong Xiao, and Tomoko Yaeshima, and Keiji Iwatsuki
Food Science and Technology Institute, Morinaga Milk Industry Co., Ltd., Kanagawa, Japan. n-iwabuchi@morinagamilk.co.jp

We investigated whether the oral administration of Bifidobacterium longum BB536 could ameliorate influenza virus (IFV) infection in a mice model. Mice were orally administrated BB536 or saline for 2 weeks and then infected with IFV. Orally administered BB536 significantly alleviated symptoms, reduced the loss of body weight, and inhibited viral proliferation in the lungs relative to the control group findings. Histopathological findings in the lungs were improved in the BB536 group compared to control group findings. There was no significant difference in the levels of interleukin-6 (IL-6), interferon-γ (IFN-γ), IL-10 and IL-12p40 in the lungs between the groups, but the levels of IL-6 and IFN-γ were lower (p=0.076, 0.103, respectively) in the BB536 group compared with those of control group. The levels of IL-6 and IL-10 correlated significantly with the values of weight loss, and the levels of IFN-γ correlated with the virus titers in the lungs. These results suggested the potential of the oral administration of BB536 in ameliorating IFV infection and the possible involvement of anti-inflammatory effects of BB536 in the anti-infection effects against IFV.

UI MeSH Term Description Entries
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D009975 Orthomyxoviridae A family of RNA viruses causing INFLUENZA and other respiratory diseases. Orthomyxoviridae includes INFLUENZAVIRUS A; INFLUENZAVIRUS B; INFLUENZAVIRUS C; INFLUENZAVIRUS D; ISAVIRUS; and THOGOTOVIRUS. Influenza Viruses,Myxoviruses,Orthomyxoviruses,Influenza Virus,Myxovirus,Orthomyxovirus
D009976 Orthomyxoviridae Infections Virus diseases caused by the ORTHOMYXOVIRIDAE. Orthomyxovirus Infections,Infections, Orthomyxoviridae,Infections, Orthomyxovirus,Swine Influenza,Infection, Orthomyxoviridae,Infection, Orthomyxovirus,Influenza, Swine,Orthomyxoviridae Infection,Orthomyxovirus Infection
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D005260 Female Females
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000893 Anti-Inflammatory Agents Substances that reduce or suppress INFLAMMATION. Anti-Inflammatory Agent,Antiinflammatory Agent,Agents, Anti-Inflammatory,Agents, Antiinflammatory,Anti-Inflammatories,Antiinflammatories,Antiinflammatory Agents,Agent, Anti-Inflammatory,Agent, Antiinflammatory,Agents, Anti Inflammatory,Anti Inflammatories,Anti Inflammatory Agent,Anti Inflammatory Agents

Related Publications

Noriyuki Iwabuchi, and Jin-Zhong Xiao, and Tomoko Yaeshima, and Keiji Iwatsuki
September 2023, Journal of food science,
Noriyuki Iwabuchi, and Jin-Zhong Xiao, and Tomoko Yaeshima, and Keiji Iwatsuki
November 2013, The British journal of nutrition,
Noriyuki Iwabuchi, and Jin-Zhong Xiao, and Tomoko Yaeshima, and Keiji Iwatsuki
March 2008, Journal of applied microbiology,
Noriyuki Iwabuchi, and Jin-Zhong Xiao, and Tomoko Yaeshima, and Keiji Iwatsuki
January 2023, Journal of inflammation research,
Noriyuki Iwabuchi, and Jin-Zhong Xiao, and Tomoko Yaeshima, and Keiji Iwatsuki
January 2010, Bioscience, biotechnology, and biochemistry,
Noriyuki Iwabuchi, and Jin-Zhong Xiao, and Tomoko Yaeshima, and Keiji Iwatsuki
March 1999, Clinical and diagnostic laboratory immunology,
Noriyuki Iwabuchi, and Jin-Zhong Xiao, and Tomoko Yaeshima, and Keiji Iwatsuki
December 2011, Virology journal,
Noriyuki Iwabuchi, and Jin-Zhong Xiao, and Tomoko Yaeshima, and Keiji Iwatsuki
January 2022, Frontiers in microbiology,
Noriyuki Iwabuchi, and Jin-Zhong Xiao, and Tomoko Yaeshima, and Keiji Iwatsuki
July 2010, Letters in applied microbiology,
Copied contents to your clipboard!